Biologic
RCSB PDB 7URV
Axicabtagene ciloleucel
Yescarta
- Mechanism of action
- Autologous anti-CD19 CAR-T cell therapy
- In plain language
- Your own T-cells are removed from your blood, genetically reprogrammed in a lab to recognize a marker called CD19 found on certain lymphoma cells, then multiplied and infused back into you to seek out and destroy those cells.
- How it works
- Autologous T cells are collected via leukapheresis, then genetically modified ex vivo through retroviral transduction to express a chimeric antigen receptor combining an anti-CD19 single-chain variable fragment with CD28 and CD3-zeta costimulatory domains. The transduced cells are expanded in culture and cryopreserved before shipment back to the treatment center. Prior to infusion, patients undergo lymphodepleting chemotherapy to reduce endogenous lymphocytes and create a favorable environment for CAR-T expansion. Upon reinfusion, CAR engagement with CD19-expressing B cells drives T-cell activation, proliferation, and cytotoxic elimination of the target cells.
- Therapeutic applications
- Indicated for adult patients with large B-cell lymphoma refractory to first-line chemoimmunotherapy or relapsed after two or more lines of systemic therapy, and for adults with relapsed/refractory follicular lymphoma after two or more lines of systemic therapy.
- Class
- CAR-T cell therapy
- Therapeutic area
- Oncology (B-cell lymphoma)
View